Microsens seeks resources to move CJD (Creutzfeldt-Jakob disease) blood test forward
This article was originally published in Clinica
Executive Summary
UK company Microsens Biotechnologies says that it is currently expanding studies of its ligand-based Seprion technology, which can detect abnormal prion proteins in the blood of patients with suspected vCJD, to include more samples.